EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Vernal keratoconjunctivitis: A clinical spectrum and newer treatment modalities

Sucheta Parija, Soumya Sucharita Panda

Odisha Journal of Ophthalmology · 2026-07 · 33 (2) · 64-71

DOI: 10.4103/odjo.odjo_28_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Odisha Journal of Ophthalmology, online erschienen am 09.11.2026. Verfasst von Sucheta Parija und 1 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vernal keratoconjunctivitis (VKC) is a chronic, progressive, and potentially sight-threatening form of ocular inflammatory disease. It predominantly affects children and young males in warm and tropical climates . It accounts for approximately 1% of ocular diseases in developed countries, and its burden is significantly higher in developing and tropical regions. Although most cases improve after puberty, persistent or severe disease can cause shield ulcers, corneal scarring, limbal stem cell dysfunction, keratoconus, and treatment-related complications. Many cases are diagnosed late, and standard therapy is often delayed until the disease has progressed and symptoms are seriously impairing patients’ quality of life. VKC is immunologically heterogeneous and involves type-2 inflammation, mast cells, eosinophils, T lymphocytes, epithelial dysfunction, and tissue remodeling; a substantial proportion of patients lack demonstrable allergic sensitization. VKC is a recurrent, seasonally exacerbated inflammation of the conjunctiva and cornea; when inadequately managed, it may result in severe corneal visual-threatening complications. Recent treatments now include immunomodulators such as cyclosporine and tacrolimus alongside conventional dual-acting antihistamine–mast cell stabilizers. Newer therapies like biologic agents such as omalizumab and dupilumab offer a more targeted and steroid-sparing approach in patients who are inadequately controlled with conventional drug therapy. Ongoing challenges include early diagnosis and optimizing long-term, safe management strategies.

Zitieren

APA

Parija, S., & Panda, S. S. (2026). Vernal keratoconjunctivitis: A clinical spectrum and newer treatment modalities. Odisha Journal of Ophthalmology, 33(2), 64-71. https://doi.org/10.4103/odjo.odjo_28_26

Vancouver

Parija S, Panda SS. Vernal keratoconjunctivitis: A clinical spectrum and newer treatment modalities. Odisha Journal of Ophthalmology. 2026;33(2):64-71. doi:10.4103/odjo.odjo_28_26

BibTeX
@article{Parija2026,
  author = {Parija, Sucheta and Panda, Soumya Sucharita},
  title = {Vernal keratoconjunctivitis: A clinical spectrum and newer treatment modalities},
  journal = {Odisha Journal of Ophthalmology},
  year = {2026},
  volume = {33},
  number = {2},
  pages = {64--71},
  doi = {10.4103/odjo.odjo_28_26}
}
Kostenlos starten →